Biotech stocks are riding a wave of volatility, with major players like Eli Lilly and Gilead seeing strong momentum thanks to acquisitions and clinical breakthroughs.
The NBI Index is stabilizing, testing resistance levels, while the XBI ETF remains in a downtrend but shows early signs of a reversal.
Big Pharma is on a buying spree, with Merck eyeing Spri…
Listen to this episode with a 7-day free trial
Subscribe to The Biotech Capital Compass to listen to this post and get 7 days of free access to the full post archives.
